| Data | Ora | Fonte | Titolo | Simbolo | Compagnia |
| 10/03/2025 | 21:17 | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:IMCR | Immunocore Holdings PLC |
| 10/03/2025 | 20:00 | GlobeNewswire Inc. | Immunocore presents initial multiple ascending dose data for HIV functional cure candidate in an oral presentation at CROI 2025 | NASDAQ:IMCR | Immunocore Holdings PLC |
| 03/03/2025 | 13:00 | GlobeNewswire Inc. | Immunocore to present at upcoming investor conferences | NASDAQ:IMCR | Immunocore Holdings PLC |
| 27/02/2025 | 22:31 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:IMCR | Immunocore Holdings PLC |
| 27/02/2025 | 22:29 | Edgar (US Regulatory) | Form 3 - Initial statement of beneficial ownership of securities | NASDAQ:IMCR | Immunocore Holdings PLC |
| 26/02/2025 | 13:00 | Edgar (US Regulatory) | Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] | NASDAQ:IMCR | Immunocore Holdings PLC |
| 26/02/2025 | 13:00 | GlobeNewswire Inc. | Immunocore reports fourth quarter and full year 2024 financial results and provides a business update | NASDAQ:IMCR | Immunocore Holdings PLC |
| 19/02/2025 | 13:00 | GlobeNewswire Inc. | Immunocore to report fourth quarter and full year 2024 financial results and host call on February 26, 2025 | NASDAQ:IMCR | Immunocore Holdings PLC |
| 10/01/2025 | 13:00 | GlobeNewswire Inc. | Immunocore announces strategic priorities at 43rd Annual J.P. Morgan Healthcare Conference | NASDAQ:IMCR | Immunocore Holdings PLC |
| 06/01/2025 | 13:00 | GlobeNewswire Inc. | Immunocore to present at the 43rd Annual J.P. Morgan Healthcare Conference | NASDAQ:IMCR | Immunocore Holdings PLC |
| 02/01/2025 | 13:00 | GlobeNewswire Inc. | Immunocore appoints Travis Coy, previously a Non-Executive Director, as its EVP, Chief Financial Officer and Head of Corporate Development | NASDAQ:IMCR | Immunocore Holdings PLC |
| 23/12/2024 | 13:00 | GlobeNewswire Inc. | Immunocore announces first patient dosed in the Phase 1 trial of IMC-P115C, a half-life extended (HLE) ImmTAC candidate in patients with tumors that express PRAME | NASDAQ:IMCR | Immunocore Holdings PLC |
| 17/12/2024 | 13:00 | GlobeNewswire Inc. | Immunocore announces treatment of first patient in the Phase 1/2 trial of IMC-R117C targeting PIWIL1 in advanced gastrointestinal cancers | NASDAQ:IMCR | Immunocore Holdings PLC |
| 11/12/2024 | 13:00 | GlobeNewswire Inc. | EORTC and Immunocore announce enrolment of first patient onto the only active Phase 3 adjuvant trial in uveal melanoma | NASDAQ:IMCR | Immunocore Holdings PLC |
| 03/12/2024 | 07:00 | GlobeNewswire Inc. | Immunocore announces reimbursement agreement in England for KIMMTRAK▼ for the treatment of HLA-A*02:01-positive adults with unresectable or metastatic uveal melanoma | NASDAQ:IMCR | Immunocore Holdings PLC |
| 06/11/2024 | 13:00 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] | NASDAQ:IMCR | Immunocore Holdings PLC |
| 06/11/2024 | 13:00 | GlobeNewswire Inc. | Immunocore reports third quarter financial results and provides a business update | NASDAQ:IMCR | Immunocore Holdings PLC |
| 14/09/2024 | 09:00 | GlobeNewswire Inc. | Immunocore presents Phase 1 data of brenetafusp, an ImmTAC bispecific targeting PRAME, in patients with ovarian cancer | NASDAQ:IMCR | Immunocore Holdings PLC |
| 12/09/2024 | 22:05 | GlobeNewswire Inc. | Immunocore to present at the 2024 Cantor Global Healthcare Conference | NASDAQ:IMCR | Immunocore Holdings PLC |
| 10/09/2024 | 19:49 | Edgar (US Regulatory) | Form SC 13G - Statement of Beneficial Ownership by Certain Investors | NASDAQ:IMCR | Immunocore Holdings PLC |
| 29/08/2024 | 13:00 | GlobeNewswire Inc. | Immunocore announces transition of Chief Financial Officer | NASDAQ:IMCR | Immunocore Holdings PLC |
| 08/08/2024 | 13:00 | GlobeNewswire Inc. | Immunocore reports second quarter financial results and provides a business update | NASDAQ:IMCR | Immunocore Holdings PLC |
| 01/08/2024 | 13:00 | GlobeNewswire Inc. | Immunocore to report second quarter 2024 financial results and host call on August 8, 2024 | NASDAQ:IMCR | Immunocore Holdings PLC |
| 18/06/2024 | 13:00 | GlobeNewswire Inc. | Immunocore announces randomization of first patient in the global, registrational Phase 3 clinical trial testing brenetafusp for the treatment of first-line advanced or metastatic cutaneous melanoma | NASDAQ:IMCR | Immunocore Holdings PLC |
| 01/06/2024 | 14:00 | GlobeNewswire Inc. | Immunocore presents KIMMTRAK clinical data demonstrating that patients with stable disease and confirmed tumor reduction have similar clinical outcomes to patients with partial response | NASDAQ:IMCR | Immunocore Holdings PLC |
| 31/05/2024 | 22:05 | GlobeNewswire Inc. | Immunocore reports updated Phase 1 data of brenetafusp (IMC-F106C), an ImmTAC bispecific targeting PRAME, in immune checkpoint pre-treated cutaneous melanoma patients at ASCO 2024 | NASDAQ:IMCR | Immunocore Holdings PLC |
| 30/05/2024 | 22:00 | GlobeNewswire Inc. | Immunocore to present at the Jefferies Global Healthcare Conference | NASDAQ:IMCR | Immunocore Holdings PLC |
| 29/05/2024 | 13:00 | GlobeNewswire Inc. | Immunocore converts Phase 2/3 TEBE-AM clinical trial into registrational Phase 3 trial evaluating KIMMTRAK for previously treated advanced cutaneous melanoma | NASDAQ:IMCR | Immunocore Holdings PLC |
| 08/05/2024 | 13:00 | GlobeNewswire Inc. | Immunocore reports first quarter financial results and provides a business update | NASDAQ:IMCR | Immunocore Holdings PLC |
| 24/04/2024 | 16:00 | GlobeNewswire Inc. | Immunocore announces upcoming presentation and posters at ASCO 2024 | NASDAQ:IMCR | Immunocore Holdings PLC |
